Dare Bioscience (DARE) Receivables - Net (2013 - 2022)

Dare Bioscience's (DARE) quarterly Receivables - Net came in at $10.0 million in Q2 2022, up 1023.6% on a QoQ basis from $890000.0 in Q2 2017.

Dare Bioscience (DARE) Receivables - Net (2013 - 2022) Analysis & Trends

Dare Bioscience (DARE) has 6 years of Receivables - Net data on file, last reported at $10.0 million in Q2 2022.

Quarterly Receivables - Net changed N/A year-over-year to $10.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $10.0 million (changed N/A YoY) and the FY2016 annual result came in at $1.8 million, up 31.99% from the prior year.
Receivables - Net advanced to $10.0 million in Q2 2022, from $890000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $10.0 million in Q2 2022 to a low of $10.0 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.18 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.98 Bn	77.98 Bn	3.93 Bn
3	Argenx Se	64.37 Bn	59.19 Bn	1.37 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
7	BioNTech SE	27.75 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.24 Bn	26.08 Bn	358.27 Mn
9	Royalty Pharma	27.03 Bn	26.20 Bn	-
10	Dare Bioscience	12.21 Mn	-406,442.64	-132,343.00

Download Data